<SEC-DOCUMENT>0000078003-25-000040.txt : 20250212
<SEC-HEADER>0000078003-25-000040.hdr.sgml : 20250212
<ACCEPTANCE-DATETIME>20250212144808
ACCESSION NUMBER:		0000078003-25-000040
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250212
DATE AS OF CHANGE:		20250212

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardiff Oncology, Inc.
		CENTRAL INDEX KEY:			0001213037
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				272004382
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-80378
		FILM NUMBER:		25614293

	BUSINESS ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-952-7570

	MAIL ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trovagene, Inc.
		DATE OF NAME CHANGE:	20130304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrovaGene Inc.
		DATE OF NAME CHANGE:	20110830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XENOMICS INC
		DATE OF NAME CHANGE:	20040719

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		66 HUDSON BOULEVARD EAST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001-2192
		BUSINESS PHONE:		2127332323

	MAIL ADDRESS:	
		STREET 1:		66 HUDSON BOULEVARD EAST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001-2192

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <!-- Generated by Workiva -->
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0000078003-21-000112</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0000078003</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock, $0.0001 par value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001213037</issuerCik>
        <issuerName>Cardiff Oncology, Inc.</issuerName>
        <issuerCusip>14147L108</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>11055 Flintkote Avenue</com:street1>
          <com:city>San Diego</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92121</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Pfizer Inc. 13-5315170</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>2411575.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>2411575.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2411575.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>3.6</classPercent>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
      <comments>(See row 11) Based on 66,524,182 shares of Common Stock outstanding as reported in the Issuer's prospectus supplement, filed with the U.S. Securities and Exchange Commission (the "Commission") on December 10, 2024, to the Issuer's effective shelf registration statement on Form S-3, which was originally filed with the Commission on April 25, 2022 (File No. 333-264148).</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Cardiff Oncology, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>11055 Flintkote Avenue, San Diego, CA, 92121</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Pfizer Inc.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>66 Hudson Boulevard East, New York, NY 10001</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Delaware, U.S.A.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>See rows 5 through 11 of the cover page.</amountBeneficiallyOwned>
        <numberOfSharesPersonHas/>
      </item4>
      <item5>
        <notApplicableFlag>N</notApplicableFlag>
        <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Pfizer Inc. 13-5315170</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Madelyn D. Purcell</signature>
        <title>Madelyn D. Purcell/Assistant Secretary</title>
        <date>02/12/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
